Rockwell Medical (RMTI) Cash from Financing Activities (2010 - 2026)
Rockwell Medical (RMTI) posted Cash from Financing Activities of -$813000.0 for Q1 2026, up 23.23% on a QoQ basis from -$1.1 million in Q4 2025, and down 3.83% year-over-year from -$845390.4 in Q1 2025.
Rockwell Medical (RMTI) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Rockwell Medical's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$813000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 3.83% year-over-year to -$813000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (down 33.9% YoY) and the FY2025 annual result came in at $4.3 million, down 42.13% from the prior year.
- Cash from Financing Activities was -$813000.0 for Q1 2026 at Rockwell Medical, up from -$1.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $26.8 million in Q2 2022 and bottomed at -$6.0 million in Q4 2022.
- A 5-year average of $2.3 million and a median of -$631000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 447150.0% — and 2025, when it plunged 539.89%.
- Rockwell Medical's Cash from Financing Activities stood at -$6.0 million in 2022, then jumped by 87.6% to -$742000.0 in 2023, then soared by 476.28% to $2.8 million in 2024, then sank by 137.93% to -$1.1 million in 2025, then climbed by 23.23% to -$813000.0 in 2026.
- Business Quant data shows RMTI's Cash from Financing Activities at -$813000.0 in Q1 2026, -$1.1 million in Q4 2025, and $6.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Rockwell Medical | 25.77 Mn | 1.88 Mn | 2.90 Mn | -813,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -813,000.00 |
| Mar 31, 2026 | -813,000.00 |
| Dec 31, 2025 | -1.06 Mn |
| Dec 31, 2025 | -1.06 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | -650,000.00 |
| Jun 30, 2025 | -650,000.00 |
| Mar 31, 2025 | -783,000.00 |
| Mar 31, 2025 | -783,000.00 |
| Dec 31, 2024 | 2.79 Mn |
| Dec 31, 2024 | 2.79 Mn |
| Sep 30, 2024 | 2.31 Mn |
| Sep 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 178,000.00 |
| Mar 31, 2024 | 178,000.00 |
| Dec 31, 2023 | -742,000.00 |
| Dec 31, 2023 | -742,000.00 |